You have read all your free articles, to continue reading subscribe to read the rest of this content.
Orexo has entered into an exclusive licensing agreement with Accord Healthcare, for the commercialization of ZUBSOLV ((buprenorphine (as hydrochloride) and naloxone (as hydrochloride dihydrate)) sublingual tablet. Licensed in Europe, ZUBSOLV is indicated for adults and adolescents over 15 years oAlready a subscriber Login You have read all your free articles,…
The company has received a positive outcome from the NAD (National Advertising Division) regarding a challenge filed on Fungi-Nail, the largest US competitor to the Kerasal Nail product. NAD recommends the advertiser to discontinue current product packaging and commercials. Moberg Pharma expects Already a subscriber Login You have read all…
The companies have signed a large-scale manufacturing agreement for the main drug intermediate in the supply of clinical material for Oasmia's investigational drug candidate, Cantrixil. “We are excited to have partnered with Lonza, a global leader in drug manufacturing. The manufacture of CantrAlready a subscriber Login You have read all…
The US Food and Drug Administration (FDA) has granted priority review for the company's New Drug Application seeking approval of melflufen in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, oneAlready a subscriber Login You have…
